Pharmaceutical industry news

Biotech Trial Wins Sent Roivant And Pharvaris Higher

As FDA Sets AI Principles for Drug Development, How Much Evidence Is Enough?

Trump Administration Names Permanent Leaders at FDA Amid Ongoing Controversies

Pharvaris stock jumps after positive HAE drug t...

Appeals Court to Rule Soon on Marijuana Rescheduling as Billions in Cannabis Tax Benefits Hang in the Balance

Semaglutide Improves BMI Category in Phase 3 Pediatric Obesity Trial

Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement

HHS Announces Key Leadership Selections at FDA to Promote Innovation, Reform, and National Health Priorities

Appeals Court to Rule Soon on Marijuana Rescheduling as Billions in Cannabis Tax Benefits Hang in the Balance

Quantum BioPharma’s Lucid-MS Gets FDA Clearance for Phase 2 Trial in Multiple Sclerosis

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

Novartis Suffers Third Clinical Setback in a Week, Wiping Out Over $40 Billion in U.S. Market Value in a Single Day

Why a cannabis business is betting on dogs to reach FDA approval

Pneumococcal vaccination for older adults and for individuals in a clinical risk group: for healthcare practitioners

Information for healthcare practitioners on delivering the pneumococcal vaccination programme for ol...

House advances Carter’s bipartisan bill to reduce animal testing in drug development

Maharashtra FDA Enforces Zero Tolerance with Major Food Safety Crackdown

Nuevos proyectos de consulta para la opinión pública

Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons

Green shoots for UK pharma investment, but delivery will decide whether they take root

Ionis Pharmaceuticals gets $85 price target des...

X4 Pharma Gains FDA Agreement to Cut Phase 3 Trial Size to 76 Patients

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Gram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, 2025 to 2026

MRSA, MSSA, Gram-negative bacteraemia infections by organisation and location of onset, and Clostrid...

Annual flu programme

Seasonal influenza (flu) is an unpredictable but recurring pressure that the NHS faces every winter....

Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness

Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Liver cancer patients appear to be living longer in a Can-Fite trial

Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Market Eyes Growth Potential

Enregistrement des antibiotiques dans VAMREG : e-learning pour les vétérinaires

Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints

XFOR Gains FDA Nod for Reduced Trial Size in Pivotal Phase 3 Study

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

BioVie Announces Next Stage of FDA Engagement for Phase 3 Parkinson’s Disease Program Evaluating Bezisterim

Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis

Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026

BioVie seeks FDA feedback on a proposed Parkinson’s trial of about 175 patients.

BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Oncologists say newly approved pancreatic cancer drug is a breakthrough for treatment

OKYO Pharma (NASDAQ: OKYO) readies Phase 3 trial of eye-pain drug urcosimod

A $50 million payment is coming to Monte Rosa as Novartis starts a Sjögren’s trial

A new trial for eye-related muscle weakness is planned for 2027. Vor Bio finished enrolling another.

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vaccine update

Vaccination newsletter for health professionals and immunisation practitioners.

Vaccine update: issue 375, Flu Special 2026

Latest developments in vaccines, vaccination policies and procedures for immunisation practitioners.

Up to 200,000 people live with this lung disease. Roivant starts a new trial.

Tukaram Mundhe's FDA Steps Up Drug Crackdown In Maharashtra: Complaints Jump 557% In 3 Months

Novartis’ $12bn Avidity bet falters on late-stage del-desiran flop

Γενόσημα Ιουλίου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευση

Novartis Heart Drug Fails Phase 3 Trial: Cutting Genetic Ch…

Στοιχεία εκτέλεσης προϋπολογισμού ΕΟΦ μηνός Ιουλίου 2026

Η PRAC ξεκινά την ανασκόπηση της ασφάλειας των ενέσιμων φαρμάκων που περιέχουν σίδηρο

Characteristics of people infected with toxigenic C. ulcerans

Characteristics of people with confirmed toxigenic C. ulcerans infection following close or direct c...

UKHSA evidence reviews

Evidence reviews conducted by the All Hazards Public Health Response Evidence Review team and the Sc...

ครึ่งเก้า จับมือ AME ร่วมทุนตั้ง Bridge Management

Pharma major Novartis falls 10% after three drug trial setbacks

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing

Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test